Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531]
In development [GID-TA10451] Expected publication date: TBC
Search results
668 results
-
-
Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management
In development [GID-NG10091] Expected publication date: 21 April 2021
-
Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]
In development [GID-TA10472] Expected publication date: 02 June 2021
-
Durvalumab in combination for untreated extensive stage small-cell lung cancer [ID1618]
In development [GID-TA10493] Expected publication date: TBC
-
Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) [ID1572]
In development [GID-TA10513] Expected publication date: TBC
-
Berotralstat for preventing acute attacks of hereditary angioedema [ID1624]
In development [GID-TA10650] Expected publication date: 25 August 2021
-
Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]
In development [GID-TA10612] Expected publication date: 21 July 2021
-
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy [ID3735]
In development [GID-TA10624] Expected publication date: 23 June 2021
-
Glasdegib with chemotherapy for untreated acute myeloid leukaemia [ID1334]
In development [GID-TA10314] Expected publication date: TBC
-
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357
In development [GID-TA10322] Expected publication date: TBC
-
Relugolix with oestradiol and norethindrone acetate for heavy menstrual bleeding associated with uterine fibroids [ID3842]
In development [GID-TA10734] Expected publication date: 09 March 2022
-
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
In development [GID-TA10467] Expected publication date: TBC
-
Pembrolizumab for advanced, unresectable or metastatic urothelial cancer (CDF review of TA522) [ID1634]
In development [GID-TA10710] Expected publication date: TBC
-
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer (CDF Review of TA557) [ID1584]
In development [GID-TA10529] Expected publication date: 10 March 2021
-
Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]
In development [GID-TA10495] Expected publication date: 18 August 2021
-
Tebentafusp for treating metastatic or unresectable HLA-A*02:01 positive uveal melanoma [ID1441]
In development [GID-TA10428] Expected publication date: 20 July 2022
-
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MT241)
In development [GID-MT548] Expected publication date: 04 May 2021
-
Acalabrutinib for untreated and treated chronic lymphocytic leukaemia [ID1613]
In development [GID-TA10532] Expected publication date: 21 April 2021
-
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 alterations [ID3740]
In development [GID-TA10619] Expected publication date: TBC
-
MT476 UroShield for preventing catheter-associated urinary tract infections
In development [GID-MT560] Expected publication date: 15 March 2022
-
QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography
In development [GID-DG10034] Expected publication date: TBC
-
Secukinumab for treating plaque psoriasis in children and young people [ID1669]
In development [GID-TA10554] Expected publication date: 20 October 2021
-
Galcanezumab for preventing cluster headache [ID1212]
In development [GID-TA10425] Expected publication date: 24 February 2021
-
MT582 AnaConDa-S for sedation with volatile anaesthetics in intensive care
In development [GID-MT556] Expected publication date: 23 February 2022
-
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in adults with elevated triglycerides [ID3831]
In development [GID-TA10736] Expected publication date: 05 January 2022
-
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1647]
In development [GID-TA10703] Expected publication date: 21 July 2021
-
Nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer [ID3757]
In development [GID-TA10632] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429
In development [GID-TA10512] Expected publication date: 22 June 2022
-
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (CDF review of TA593) [ID3755]
In development [GID-TA10675] Expected publication date: 31 March 2021
-
Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1581]
In development [GID-TA10740] Expected publication date: 13 July 2022
-
EarlyCDT Lung for lung cancer risk classification of solid pulmonary nodules
In development [GID-DG10041] Expected publication date: 23 February 2022
-
Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]
In development [GID-TA10567] Expected publication date: 14 September 2022
-
Selective internal radiation therapies for treating hepatocellular carcinoma [ID1276]
In development [GID-TA10381] Expected publication date: 31 March 2021
-
Sapropterin for treating phenylketonuria [ID1475]
In development [GID-TA10378] Expected publication date: 16 June 2021
-
Blinatumomab for treating Philadelphia-chromosome-positive relapsed or refractory acute lymphoblastic leukaemia [ID1008]
In development [GID-TA10119] Expected publication date: TBC
-
Perineal biopsy devices for diagnosis of prostate cancer in people with suspected prostate cancer [provisional title]
In development [GID-DG10043] Expected publication date: TBC
-
Danis Stent for acute oesophageal variceal bleeds (MT450)
In development [GID-MT537] Expected publication date: 08 April 2021
-
Percutaneous insertion of a closure device to repair a paravalvular leak around a replaced mitral or aortic valve
In development [GID-IPG10150] Expected publication date: 23 June 2021
-
Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus)
In development [GID-IPG10161] Expected publication date: 23 June 2021
-
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
In development [GID-TA10592] Expected publication date: TBC
-
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
In development [GID-TA10596] Expected publication date: 15 December 2021
-
Esketamine for treatment-resistant depression (ID1414)
In development [GID-TA10371] Expected publication date: TBC
-
Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]
In development [GID-TA10334] Expected publication date: TBC
-
Antenatal care
In development [GID-NG10096] Expected publication date: 11 August 2021
-
GID-MT550 DyeVert for reducing contrast media in coronary and peripheral angiography (MT488)
In development [GID-MT550] Expected publication date: 04 October 2021
-
Amivantamab for treating EGFR Exon 20 insertion-positive non-small-cell lung cancer after platinum-based chemotherapy [ID3836]
In development [GID-TA10729] Expected publication date: TBC
-
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]
In development [GID-TA10481] Expected publication date: 18 August 2021
-
Multiple myeloma - lenalidomide (maintenance, post autologous stem cell transplantation) [ID475]
In development [GID-TAG430] Expected publication date: 03 March 2021
-
Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]
In development [GID-TA10697] Expected publication date: TBC
-
Head injury: assessment and early management
In development [GID-NG10164] Expected publication date: 11 May 2022